TrialFinder  /  Landscape Report SUICIDE  ·  2026-10-26 Revasser  /  revasserkernel.com
Landscape Report TrialFinder
SOURCE  ClinicalTrials.gov API v2
GENERATED  2026-10-26
VERSION  v1
SAMPLE  100 of 1798 studies

suicide

The suicide clinical trial landscape includes 1798 actively recruiting trials. Semantic expansion identified 1627 additional trials beyond exact-match search, representing a 951.5% discovery lift across related conditions and therapeutic approaches.

Recruiting
1798
active trials
Expansion Lift
+951.5%
1627 additional trials
Top Sponsor
Centre for Addiction and Mental Health
4 trials
Dominant Phase
NA
66 of 101 sampled
Pipeline Overview
Phase Distribution
NA
66
Early I
1
Phase 1
4
Phase 2
9
Phase 3
5
Phase 4
5
Other
11
Therapeutic Modalities
BEHAVIORAL
68
DEVICE
32
OTHER
31
DRUG
31
DIAGNOSTIC_TEST
8
DIETARY_SUPPLEMENT
4
PROCEDURE
2
GENETIC
1
Recruiting vs. Completed (2yr)
Recruiting
1798
Completed
973
Competitive Landscape
Sponsor Classification
79%
10%
10%
OTHER (31)
FED (4)
NIH (4)
Top Sponsors
SponsorTrialsClass
Centre for Addiction and Mental Health4OTHER
University of Alabama at Birmingham4OTHER
VA Office of Research and Development4FED
University of California, San Francisco4OTHER
University of California, Los Angeles3OTHER
National Institute of Mental Health (NIMH)2NIH
National Institute on Drug Abuse (NIDA)2NIH
Stanford University2OTHER
Mayo Clinic2OTHER
Medical University of South Carolina2OTHER
University of Massachusetts, Worcester2OTHER
Weill Medical College of Cornell University2OTHER
Yale University2OTHER
University of Wisconsin, Madison2OTHER
University of British Columbia2OTHER
Geographic Distribution
Top U.S. States by Trial Density
StateTrialsTop City
California22Los Angeles
New York11New York
Florida9Miami
Maryland5Bethesda
Texas5Houston
Alabama4Birmingham
Illinois4Chicago
Connecticut4New Haven
Pennsylvania3Philadelphia
Georgia3Augusta
Ohio3Cleveland
Massachusetts3Worcester
North Carolina3Durham
Colorado3Denver
Utah3Clinton
Arkansas2Little Rock
Virginia2Richmond
Minnesota2Rochester
South Carolina2Charleston
Louisiana2New Orleans
Expansion Intelligence
+951.5%
Discovery lift — trials found by semantic expansion that exact-match search misses entirely. This is the gap competitors don't see.
3
Exact
2
Parent
3
Related
4
Comorbid
4
Therapeutic
Top Expansion Terms
  • psychiatric emergency Parent
  • mood disorder Parent
  • self-harm Related
  • deliberate self-injury Related
  • suicide attempt Related
  • major depressive disorder Comorbid
  • bipolar disorder Comorbid
  • borderline personality disorder Comorbid
  • substance use disorder Comorbid
  • ketamine suicidal ideation Therapeutic

These terms are curated from clinical literature — not generated by a language model. Each captures trials that use variant nomenclature for the same underlying condition or therapeutic area.

Key Findings
What This Landscape Means for suicide
high
Standard searches miss 952% of relevant trials for suicide — semantic expansion across related conditions and therapeutic approaches is essential for complete landscape visibility.
1627 additional trials found via expansion vs 171 exact matches
high
5 Phase 3 trials indicate a maturing pipeline with near-term approval potential.
Phase 3 represents 5% of sampled trials
Next Steps
Take Action on This Intelligence
//
Stay Current
Get alerted when new trials open for suicide and related conditions. Free tier monitors 1 condition weekly.
Set Up Alerts
[+]
Research Portal
Deploy this intelligence as your organization's permanent research hub — auto-updating, branded, zero hosting cost.
From $497
{<}
API Access
Integrate trial intelligence into your own tools. Full expansion engine, landscape analytics, real-time data.
View Plans
Top Recruiting Trials
20 actively recruiting studies
Causal Role of Delta-beta Coupling for Goal-directed Behavior in Anhedonic Depression
Florida State University n=72 Florida State University Tallahassee, Florida
Intervention DEVICE: Delta-beta tACS via the Neurocare Direct Current Stimulator Multi-Channel 4 — Stimulation will be delivered via the Neurocare Direct Current Stimulator Multi-Channel 4, an investigational electrical...
Eligibility Ages 18 Years – 65 Years
Contact Justin M Riddle, PhD · 850-645-2389 · jriddle@fsu.edu
NCT05515354 PHASE4
Smoking Cessation and Menstrual Cycle Phase
Centre for Addiction and Mental Health n=1200 Centre for Addiction and Mental Health, Nicotine Dependence Clinic Toronto, Ontario
Intervention OTHER: Timing of nicotine replacement therapy start date — Nicotine replacement therapy and abstinence from smoking are initiated at a specific period with regard to the menstrual...
Eligibility Ages 18 Years – 40 Years, FEMALE only
Contact Laurie A Zawertailo, PhD · 4165358501 · laurie.zawertailo@camh.ca
NCT07027839 PHASE1
Acute Effects of Alcohol on PET Imaging of Phosphodiesterase-4B (PDE4B)
National Institute of Mental Health (NIMH) n=30 National Institutes of Health Clinical Center Bethesda, Maryland
Intervention DRUG: Intravenous Ethanol — Intravenous ethanol infusion before PET Scan
Eligibility Ages 21 Years – 70 Years
Contact Tara N Turon, C.R.N.P. · (301) 827-6599 · tara.turon@nih.gov
In-patient SCC TMS
University of California, Los Angeles n=30 UCLA TMS Service and Research Service Los Angeles, California
Intervention DEVICE: Open-label TMS — Customized, Open-Label Transcranial Magnetic Stimulation
Eligibility Ages 18 Years – 65 Years
Contact Nikita Vincecruz, BS · 310-825-4781 · nvincecruz@mednet.ucla.edu
rTMS for Depression in Young Adults With Autism
Centre for Addiction and Mental Health n=80 Centre for Addiction and Mental Health Toronto, Ontario
Intervention DEVICE: Active Bilateral Theta Burst Stimulation — A total of 30 active BL-TBS sessions. Stimulation will begin with right DLPFC (cTBS) followed by left DLPFC (iTBS)
Eligibility Ages 16 Years – 35 Years
Contact Viviane Grassmann, PhD · 416-535-8501 · AutismTMS@camh.ca
Olfactory Function and Model-Based Behavior in People Living With HIV and SUD
National Institute on Drug Abuse (NIDA) n=120 National Institute on Drug Abuse Baltimore, Maryland
Eligibility Ages 18 Years – 65 Years
Contact NIDA IRP Screening Team · (800) 535-8254 · researchstudies@nida.nih.gov
Telehealth Behavioral Activation for Teens
Baylor College of Medicine n=250 Baylor College of Medicine Houston, Texas
Intervention OTHER: Behavioral Activation — All participants will undergo behavioral activation treatment for 8-10 weeks
Eligibility Ages 12 Years – 18 Years
Contact Emily Bivins, B.S. · 713-798-1709 · emily.bivins@bcm.edu
Reward Sensitivity Digital Intervention for Suicide Risk
University of Pennsylvania n=20 University of Pennsylvania Philadelphia, Pennsylvania
Intervention BEHAVIORAL: Suicide prevention treatment — Digital just-in-time adaptive intervention to enhance reward sensitivity and reduce suicidal ideation
Eligibility Ages 13 Years – 17 Years
Contact Sydney Lempert, B.A. · 215-746-3337 · Sydney.Lempert@Pennmedicine.upenn.edu
Socio-cognitive and Biological Responses to Maltreatment
Medical University Innsbruck n=160 Medical University of Innsbruck Innsbruck, Tyrol
Eligibility Ages 18 Years – 65 Years
Contact Noora Tuovinen, PhD · +4351250483819 · noora.tuovinen@i-med.ac.at
Evaluation of Depression Screening Methods Administered by Registered Nurses in Chronic Hemodialysis Patients
Centre Hospitalier Annecy Genevois n=450 Centre Hospitalier Annecy Genevois Annecy
Intervention OTHER: evaluate the psychometric performance of different modalities of hetero-assessment of depressive symptoms by nurses — Interventional study with minimal risks and constraints. The main objective is to evaluate the psychometric performance ...
Eligibility Ages 18 Years
Contact Alexandra Rippoz · 0033 4 85522120 · arippoz@ch-annecygenevois.fr
Cannabis Abstinence and Neurocognitive Assessment in Adolescence
University Hospital Pilsen n=29 University Hospital Pilsen Pilsen, Czechia
Intervention DIAGNOSTIC_TEST: Neurocognitive assessment — Neurocognitive battery: TMT-Trail Making Test Auditory Verbal Learning Test Stroop Test Tower of London (ToL), Shallice...
Eligibility Ages 15 Years – 18 Years
Contact Jiri Podlipny, MD, Ph.D. · +420 377 103 209 · podlipny@fnplzen.cz
HIV, Equity, and Addiction Training (HEAT) Program
University of Alabama at Birmingham n=30 University of Alabama at Birmingham Birmingham, Alabama
Intervention OTHER: Telemedicine — Routine care administered via telemedicine
Eligibility Ages 18 Years
Contact Ellen F Eaton, MD, MSPH · 2059750661 · eeaton@uabmc.edu
Primary Connections for Youth and Families
The National Center on Addiction and Substance Abuse at Columbia University n=2300 Columbia University Medical Center New York, New York
Intervention BEHAVIORAL: Standard Screening — All consented youth age 12-17 years complete a patient-facing, well-validated digital screening tool, the CRAFFT (Knight...
Eligibility Ages 12 Years – 17 Years
Contact Nicole P Porter, PhD · 212-841-5265 · nporter@toendaddiction.org
Outcome Inference in the Sensory Preconditioning Task in Opioid-Use Disorder
National Institute on Drug Abuse (NIDA) n=150 National Institute on Drug Abuse Baltimore, Maryland
Eligibility Ages 21 Years – 60 Years
Contact NIDA IRP Screening Team · (800) 535-8254 · researchstudies@nida.nih.gov
Supervision in Substance Use Disorder Treatment Programs
University of Arkansas n=43 University of Arkansas for Medical Sciences Little Rock, Arkansas
Intervention OTHER: FOCUS supervision strategy — The FOCUS supervision strategy provides a strenghts-based model for supervision. It is built around three core component...
Eligibility Ages 18 Years
Contact Jure Baloh, PhD · 501 526 6604 · jbaloh@uams.edu
NCT07105111 PHASE4
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
Neurocrine Biosciences n=100 Neurocrine Clinical Site Bryant, Arkansas
Intervention DRUG: Valbenazine — Valbenazine capsules for oral administration.
Eligibility Ages 18 Years
Contact Neurocrine Medical Information Call Center · 1-877-641-3461 · medinfo@neurocrine.com
Effect of Suicide Prevention Training for Professionals
University Ghent n=10000 Ghent University Hospital Ghent
Intervention BEHAVIORAL: Training on suicide prevention — Suicide prevention training in Flanders is organised by the Centre for the Prevention of Suicide and the suicide prevent...
Contact Gwendolyn Prof. Dr. Portzky · +3293320775 · info@vlesp.be
COpenhagen Magnetic Personalized Accelerated Brain Circuit Therapy for Treatment Resistant Depression
Danish Research Centre for Magnetic Resonance n=78 Centre of Neuropsychiatric Depression Research Glostrup Municipality
Intervention DEVICE: MagVenture XP Orange Stimulator and active side of MagVenture COOL-B65 coil. — Intermittent theta burst stimulation (iTBS) targeting the left dorsolateral prefrontal cortex (DLPFC) will be administer...
Eligibility Ages 18 Years – 95 Years
Contact Poul Videbech, Professor · +4538640634 · poul.videbech@regionh.dk
COmparison of the Use of a PERforator Flap Versus Total Skin GRAft in the Management of Loss of Substance After Resection of Cutaneous Melanoma - Pilot Study
Nantes University Hospital n=40 CHU Nantes-Department of Severe Burns and Aesthetic Surgery Nantes, Nantes
Eligibility Ages 18 Years
Contact Ugo Lancien, MD · 02 40 08 73 04 · ugo.lancien@chu-nantes.fr
Accelerated iTBS for Major Depression
Istanbul University - Cerrahpasa n=35 Istanbul University - Cerrahpasa Istanbul
Intervention DEVICE: Accelerated Intermittent Theta Burst Stimulation (iTBS) — Accelerated intermittent theta burst stimulation (iTBS) is administered bilaterally to the dorsomedial prefrontal cortex...
Eligibility Ages 18 Years – 65 Years
Contact Merve Rana Altunel Ülkü, MD · +90 506 303 10 68 · ranaltunel@gmail.com